• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Proactive news headlines including Tiziana Life Sciences, BetterLife Pharma, Silvercorp Metals and Mind Medicine

    2/2/21 10:48:35 AM ET
    $TLSA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TLSA alert in real time by email

    New York, Feb. 02, 2021 (GLOBE NEWSWIRE) -- - Tiziana Life Sciences PLC (NASDAQ:TLSA) (LON:TILS) hails positive results from Brazil coronavirus study of breakthrough nasally-administered antibody treatment click here

    - BetterLife Pharma Inc (CSE:BETR) (OTCQB:BETRF) (FRA:NPAU) files patent protection for its newest compound TD-010 to treat anxiolytic-use disorder click here

    - Heritage Cannabis Holdings Corp (CSE:CANN) (OTCQX:HERTF) (FRA:2UE) files a preliminary prospectus for an upcoming equity financing click here

    - Mirasol Resources Ltd (CVE:MRZ) (OTCPINK:MRZLF) (FRA:M8R) commences new 2,700 metre drill program at Virginia silver project in Argentina click here

    - HempFusion Wellness Inc (TSX:CBD.U) (FRA:8OO) announces exclusive partnership with racing team Loenbro Motorsports for 2021 season click here

    - Mind Medicine (MindMed) Inc (NEO:MMED) (OTCQB:MMEDF) (FRA:MMQ) unveils changes at the top as it advances its psychedelic medicine strategy click here

    - Nabis Holdings Inc (CSE:NAB) (OTCMKTS:NABIF) (FRA:A2PL) provides update on its Arizona cannabis operations; settles lawsuit click here

    - Silvercorp Metals Inc (TSX:SVM) (NYSEAMERICAN:SVM) (FRA:S9Y) subsidiary acquires La Yesca silver project in Mexico click here

    - Fury Gold Mines Limited (TSE:FURY) (NYSEAMERICAN:FURY) (FRA:AUN1) aims to kick off 25,000m of drilling at Homestake Ridge gold-silver project this summer click here

    - African Gold Group Inc (CVE:AGG) (OTCMKTS:AGGFF) (FRA:3A61) says latest drilling at flagship Kobada gold project augurs well for expanding resources click here

    About Proactive

    With six offices on three continents and a team of experienced business journalists and broadcasters, Proactive works with innovative growth companies quoted on the world’s major stock exchanges, helping executives engage intelligently with investors.

    Proactive’ s platform delivers the right message to the right audience, digitally and in real time, leveraging a range of media, investment research, digital investor targeting and website development services to support over 1,000 fast-growing companies globally.

    Proactive’s network reaches over 12 million engaged private, professional and institutional investors looking for opportunities.

    •           Our written and video content is published on Proactive sites that collectively attract up to 10 million views per month.

    •           We syndicate our content to hundreds of mainstream and specialist news sites that expand our reach into networks that can be difficult for press releases to penetrate.

    •           We custom build corporate websites from the ground up, empowering clients and their brands with a modern online presence and the latest insight on effective SEO strategy.

    •           Our news coverage ranks high on the world’s most popular search platforms, and we can further amplify online presence and outreach with sophisticated digital investor targeting.    

    •           We help the world understand what makes companies stand out from the crowd with in-depth investment research from a team of experienced analysts.

    For more information on how Proactive can help you make a difference, email us at [email protected]


    Get the next $TLSA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TLSA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $TLSA
    Financials

    Live finance-specific insights

    See more
    • Tiziana Life Sciences Announces Date of Annual General Meeting 2022

      NEW YORK, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announced that the 2022 Annual General Meeting of the Company will be held on December 29, 2022. The record date for voting at the Annual General Meeting is set as November 30, 2022. The notice, agenda and associated material have been despatched to shareholders via mail and the notice, agenda and related financial statements in the form of the relevant Form 20-F filing are available on the Company's website at https://ir.tizianalifesciences.com/shareholder-services/annual-ge

      12/6/22 7:00:00 AM ET
      $TLSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tiziana Life Sciences Announces Near-Term Strategic Focus on Intranasal Foralumab for Diseases of the Central Nervous System (CNS)

      NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced a corporate update, including its near-term focus on developing intranasal foralumab for inflammatory diseases of the Central Nervous System (CNS) such as non-active secondary-progressive Multiple Sclerosis (SPMS), Alzheimer's disease and amyotrophic lateral sclerosis (ALS). Gabriele Cerrone, Executive Chairman and interim Chief Executive Officer of Tiziana, remarked, "We look forward to leveraging the exciting clinical and preclinical results from our

      11/10/22 7:00:00 AM ET
      $TLSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tiziana to Host Investor Call to Discuss Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Treatment

      NEW YORK and LONDON, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ:TLSA, LSE: TILS))) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, will host a conference call and audio webcast on Wednesday, September 8, at 4:15 p.m. ET to discuss its recently announced exclusive license agreement to evaluate Foralumab, the Company's novel, fully human anti-CD3 monoclonal antibody, in conjunction with allogenic CAR T candidates for cancer treatment. Date:Wednesday, September 8, 2021  Time:4:15 p.m. Eastern Time  Live Call:+1-877-407-9716 (U.S. Toll-Free) or +1-201-493-6779 (International)

      9/7/21 2:00:00 AM ET
      $TLSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TLSA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer's Disease

      NEW YORK, May 23, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced advancements in moderate Alzheimer's disease treatment, showcased in a recent feature on a national public radio station across the United States. The advancement involves the use of Tiziana's novel nasal spray, foralumab, which is designed to combat brain inflammation, marking a step forward in moderate Alzheimer's research and treatment. In the exclusive interview, Dr. Howard Weiner

      5/23/25 7:00:00 AM ET
      $TLSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Journal of Clinical Nuclear Medicine Publishes Results of Tiziana's Nasal Foralumab in Study Treating Moderate Alzheimer's Disease

      NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the publication of a new study in the Journal of ‘Clinical Nuclear Medicine' demonstrating that intranasal administration of foralumab significantly dampened microglial activation in a 78-year old patient with moderate Alzheimer's disease (AD) treated as part of a Food and Drug Administration (FDA) expanded access program. The findings, published in the prestigious ‘Clinical Nuclear Me

      5/15/25 8:00:00 AM ET
      $TLSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tiziana Life Sciences Announces Purchase of Shares by Chairman

      NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody, today announces that its Executive Chairman and Founder, Mr. Gabriele Cerrone, has purchased 15,000 common shares at $1.55 per share, bringing his total holding to 43,252,143 common shares, which is 37.02% of issued share capital. About ForalumabForalumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate that has been shown to stimulate T regulatory cells when dosed intr

      5/12/25 7:00:00 AM ET
      $TLSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TLSA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Zacks Investment Research initiated coverage on Tiziana Life Sciences with a new price target

      Zacks Investment Research initiated coverage of Tiziana Life Sciences with a rating of Not Rated and set a new price target of $7.50

      4/12/21 11:57:17 AM ET
      $TLSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TLSA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Tiziana Life Sciences Ltd.

      SC 13G - Tiziana Life Sciences Ltd (0001723069) (Subject)

      5/4/22 4:34:27 PM ET
      $TLSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Tiziana Life Sciences plc

      SC 13D - Tiziana Life Sciences Ltd (0001723069) (Subject)

      1/4/22 4:31:31 PM ET
      $TLSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Tiziana Life Sciences plc (0001723069) (Subject)

      2/16/21 7:32:16 AM ET
      $TLSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TLSA
    Leadership Updates

    Live Leadership Updates

    See more
    • Tiziana Life Sciences Appoints New Chief Executive Officer

      NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the appointment of Ivor Elrifi as its Chief Executive Officer (CEO), effective immediately. "We are delighted to welcome Ivor Elrifi as the new CEO of Tiziana Life Sciences," said Gabriele Cerrone, Founder and Executive Chairman of the Board. " Ivor has an invaluable track record in creating substantial value for biotech and pharma companies with his strategic vision in building in

      8/19/24 7:00:00 AM ET
      $TLSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tiziana Life Sciences Scientific Board Chairman to Receive Prestigious Award for Multiple Sclerosis Research

      NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that Howard L. Weiner, M.D., Chairman of Tiziana's Scientific Advisory Board and co-director of the Ann Romney Center for Neurologic Diseases at Brigham and Women's Hospital, a founding member of Mass General Brigham healthcare system, is being honored with the prestigious "Giants of MS" award for his outstanding contributions in the area of multiple sclerosis (MS) research. The award ceremony will take place on May 30, 2024 at the Consortium of Multipl

      5/30/24 7:00:00 AM ET
      $TLSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tiziana Life Sciences Announces Appointment of William A. Clementi as Chief Development Officer

      Leadership Addition Strengthens Company's Commitment to Advancing Innovative Therapies NEW YORK, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, is pleased to announce that it has appointed William A. Clementi, Pharm.D., FCP as Chief Development Officer. Dr. Clementi will formally take up the CDO role effective September 1, 2023. In this role, Dr. Clementi will be responsible for overseeing the company's development strategies and advancing its portfolio of groundbreaking therapeutic candidates. Dr. Clementi brings with

      8/23/23 10:30:00 AM ET
      $TLSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TLSA
    SEC Filings

    See more
    • SEC Form 6-K filed by Tiziana Life Sciences Ltd.

      6-K - Tiziana Life Sciences Ltd (0001723069) (Filer)

      5/23/25 7:04:23 AM ET
      $TLSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Tiziana Life Sciences Ltd.

      6-K - Tiziana Life Sciences Ltd (0001723069) (Filer)

      5/15/25 8:00:09 AM ET
      $TLSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Tiziana Life Sciences Ltd.

      6-K - Tiziana Life Sciences Ltd (0001723069) (Filer)

      5/12/25 7:00:07 AM ET
      $TLSA
      Biotechnology: Pharmaceutical Preparations
      Health Care